Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1289-1294

  Mariam, Deneke H ^a,c   Mengistu, Yohannes ^d   Hoffner, Sven E ^a   Andersson, Dan I ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CELL LINE; CULTURE MEDIUM; GENE MUTATION; GROWTH RATE; MACROPHAGE; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE;

ANTIBIOTICS, ANTITUBERCULAR; BINDING, COMPETITIVE; CELL LINE; COLONY COUNT, MICROBIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN;

EID: 1642543134     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1289-1294.2004     Document Type: Article

References (32)

1. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6:452-456.
2. Billington, O. J., T. D. McHugh, and S. H. Gillespie. 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:1866-1869.
3. Björkman, J., D. Hughes, and D. I. Andersson. 1998. Virulence of antibiotic-resistant Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 95: 3949-3953.
4. Björkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
5. Björkholm, B., M. Sjölund, P. G. Falk, O. Berg, L. Engstrand, and D. I. Andersson. 2001. Mutation frequency and biological cost of antibiotic resistance in Helicobacterpylori. Proc. Natl. Acad. Sci. USA 98:14607-14612.
6. Böttger, E. C., B. Springer, M. Pletschette, and P. Sander. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 12:1343-1344.
7. Enne, V. I., D. M. Livermore, P. Stephens, and L. M. Hall. 2001. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328.
8. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, M. C. Raviglione, et al. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med. 344:1294-1303.
9. Gillespie, S. H. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46:267-274.
10. Gillespie, S. H., L. L. Voelker, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8:79-84.
11. Kiers, A., A. P. Drost, D. van Soolingen, and J. Veen. 1997. Use of DNA fingerprinting in international source case finding during a large outbreak of tuberculosis in the Netherlands. Int. J. Tuberc. Lung Dis. 1:239-245.
12. Morlock, G. P., B. B. Plikaytis, and J. T. Crawford. 2000. Characterization of spontaneous, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob. Agents Chemother. 44:3298-3301.
13. Nagaev, I., J. Björkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439.
14. Ohno, H., H. Koga, S. Kohno, T. Tashiro, and K. Hara. 1996. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob. Agents Chemother. 40:1053-1056.
15. Paul, S., P. Laochumroonvorapong, and G. Kaplan. 1996. Comparable growth of virulent and avirulent Mycobacterium tuberculosis in human macrophages in vitro. J. Infect. Dis. 174:105-112.
16. Pym, A. S., B. Saint-Joanis, and S. T. Cole. 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun. 70:4955-4960.
17. Qian, L., C. Abe, T.-P. Lin, M.-C. Yu, S.-N. Cho, S. Wang, and J. T. Douglas. 2002. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from east Asian countries. J. Clin. Microbiol. 40:1091-1094.
18. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. Tuberc. Lung Dis. 79:3-29.
19. Reynolds, M. G. 2000. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156:1471-1481.
20. Sander, P., B. Springer, T. Prammananan, A. Sturmfels, M. Kappler, M. Pletschette, and E. C. Böttger. 2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 46:1204-1211.
21. Schrag, S. J., and V. Perrot. 1996. Reducing antibiotic resistance. Nature 381:120-121.
22. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. R. Soc. London B 264:1287-1291.
23. Sherman, D. R., K. Mdluli, M. J. Hickey, T. M. Arain, C. E. Barry III, and K. C. Stover. 1996. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272:1641-1643.
24. Sjölund, M., K. Wreiber, D. I. Andersson, M. J. Blaser, and L. Engstrand. 2003. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacterpylori. Ann. Intern. Med. 139:483-487.
25. Somoskovi, A., L. M. Parsons, and M. Salfinger. 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir. Res. 2:164-168.
26. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. T. Cole, M. J. Colston, L. Matter, K. Schoolfer, and T. Bodmer. 1993. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
27. Victor, T. C., P. D. van Helden, and R. Warren. 2002. Prediction of drug resistance in M. tuberculosis: molecular mechanisms, tools, and applications. IUBMB Life 53:231-237.
28. Werngren, J., and S. E. Hoffner. 2003. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J. Clin. Microbiol. 41:1520-1524.
29. Wichelhaus, T. A., B. Böddinghaus, S. Besier, V. Schäfer, V. Brade, and A. Ludwig. 2002. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:3381-3385.
30. Yang, B., H. Koga, H. Ohno, K. Ogawa, M. Fukuda, Y. Hirakata, S. Maesaki, K. Tomono, T. Tashiro, and S. Kohno. 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42:621-628.
31. Yuen, L. K., D. Leslie, and P. J. Coloe. 1999. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J. Clin. Microbiol. 37:3844-3850.
32. Zhang, M., J. Gong, Y. Lin, and P. F. Barnes. 1998. Growth of virulent and avirulent Mycobacterium tuberculosis strains in human macrophages. Infect. Immun. 66:794-799.